Comparative Pharmacology
Head-to-head clinical analysis: CONZIP versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONZIP versus ULTRAM.
CONZIP vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic